Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
Mar 06, 2012, 09:56 ET
NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0789007/Diabetes-Therapeutics-Market-to-2017---Better-Glycemic-Control-and-Reduced-Potential-Risk-of-Hypoglycemia-to-Increase-the-Market-Share-of-DPP-IV-Inhibitors-and-GLP-1-Agonists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists" which provides insights into diabetes therapeutics sales and price forecasts until 2017. The report also examines the global diabetes therapies' treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region, and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of the two diabetes therapeutic indications, which are Type 1 and Type 2 diabetes. In addition, it includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.
The global diabetes market is growing rapidly due to the increasing diabetes population in the developed countries of the US, the UK and Germany. In 2010, the global diabetes market was estimated at $29.3 billion, representing a compound annual growth rate (CAGR) of 10.0% between 2003 and 2010. The diabetes Type 2 market, with sales worth $21.0 billion in 2010, accounted for 72% of the total diabetes market. Insulin analogues dominated the market, followed by oral hypoglycemic agents. By 2017, the global diabetes therapeutics market is forecast to record $47.2 billion, representing a CAGR of 7.1% between 2010 and 2017. The Type 1 diabetes market is expected to account for $13.2 billion, and the Type 2 diabetes market is expected to account for $34.0 billion in 2017.
GBI Research finds that the global diabetes therapeutics market is dominated by Novo Nordisk, Sanofi and Takeda, which contribute almost 60% of the market share in the global diabetes market. The competitive landscape in the market is set to change due to the success of recent launches and the potential success of new drugs that will be launched during the period 2010-2017. The market will also be impacted by the decline in the sales of leading products such as GlaxoSmithKline's Avandia and Takeda's Actos.
GBI Research estimates that the market share of Eli Lilly and Merck in the diabetes market will increase due to the potential success of Teplizumab, which is in Phase III, and Januvia, which was launched in 2006. In addition, Novo Nordisk's Victoza is expected to give tough competition to Merck's Januvia and is expected to generate sales of $1.4 billion by 2014.
Scope
- Data and analysis on the diabetes therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the diabetes therapeutics market from 2003 to 2010, with forecasts to 2017 for Type 1 and Type 2 diabetes.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as prevalence population, treatment seeking population, diagnosed population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- Market share analysis of the top companies and the drug classes in 2010 and their forecasts in 2017.
- Competitive landscape of the global diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, GlaxoSmithKline and Amylin Pharmaceuticals.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that can fill their portfolio gaps.
- Align the product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Diabetes Therapeutics Market to 2017 - Introduction 11
2.1 GBI Research Report Guidance 12
3 Diabetes Therapeutics Market to 2017 - Market Overview 13
3.1 Introduction 13
3.2 Three Major Unmet Needs Prevalent in the Diabetes Market 13
3.2.1 Complications like Heart Risks are Associated with Some of the Oral Anti-Diabetic Drugs 13
3.2.2 Patients on Insulin Analogues are Prone to Carcinogenic Effects 14
3.2.3 Poor Patient Compliance with Anti-Diabetic Drug Therapy 14
3.3 Revenue 15
3.4 Annual Cost of Therapy (ACT) 17
3.5 Treatment Usage Patterns 19
3.5.1 Prevalence Population 21
3.5.2 Treatment Seeking Population 22
3.5.3 Diagnosed Population 23
3.5.4 Prescription Population 24
3.6 Drivers and Restraints of the Diabetes Therapeutics Market 25
3.6.1 Drivers of the Diabetes Market 25
3.6.2 Restraints for the Diabetes Market 26
3.7 Branded vs. Generic Market Share in the Global Diabetes Market 27
4 Diabetes Therapeutics Market to 2017 - Geographical Landscape 28
4.1 The US 28
4.1.1 Revenue 28
4.1.2 Annual Cost of Therapy 30
4.1.3 Treatment Usage Patterns 31
4.2 Top Five Countries of Europe 37
4.2.1 Revenue 37
4.2.2 Annual Cost of Therapy 39
4.2.3 Treatment Usage Patterns 40
4.3 Japan 46
4.3.1 Revenue 46
4.3.2 Annual Cost of Therapy 47
4.3.3 Treatment Usage Patterns 48
5 Diabetes Therapeutics Market to 2017 - Therapeutic Landscape 53
5.1 Type 1 Diabetes Market 53
5.1.1 Introduction 53
5.1.2 Symptoms 53
5.1.3 Treatment 53
5.1.4 Unmet Needs 55
5.1.5 Branded vs. Generic Market Share in the Type 1 Diabetes Market 56
5.1.6 Revenue 57
5.1.7 Annual Cost of Therapy (ACT) 58
5.1.8 Treatment Flow Algorithm for Type 1 Diabetes 60
5.1.9 Treatment Usage Patterns 61
5.1.10 Drivers and Restraints for the Type 1 Diabetes Market 66
5.2 Type 2 Diabetes Market 68
5.2.1 Introduction 68
5.2.2 Symptoms 68
5.2.3 Treatment 68
5.2.4 Unmet Needs 68
5.2.5 Branded vs. Generic Market Share in the Type 2 Diabetes Market 70
5.2.6 Revenue 70
5.2.7 Annual Cost of Therapy 72
5.2.8 Treatment Flow Algorithm for Type 2 Diabetes 73
5.2.9 Treatment Usage Patterns 74
5.2.10 Drivers and Restraints for the Type 2 Diabetes Market 79
6 Diabetes Therapeutics Market to 2017 - Pipeline Analysis 81
6.1 Introduction 81
6.1.1 Research and Development Pipeline - Type 1 Diabetes 82
6.1.2 Research and Development Pipeline - Type 2 Diabetes 89
6.2 Innovations in Diabetes Treatment 100
6.2.1 Insulin in Pills (Oral Delivery) 100
6.2.2 Promising Treatments for Diabetic Retinopathy 100
6.2.3 Biomarkers in Diabetes 100
6.2.4 Combination Drugs are an Important Part of the Diabetes Pipeline 101
6.2.5 Cellular Activation Therapy (CAT) 101
6.3 Drug Delivery in Diabetes 102
6.3.1 Factors Determining Preference for Drug Delivery 102
6.3.2 Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable 102
6.3.3 Innovation in Drug Delivery Systems 102
6.4 Profiles of Promising Drugs in the Diabetes Market 104
6.4.1 rhGAD65 (Diamyd) 104
6.4.2 Bydureon 104
6.4.3 DiaPep277 105
6.4.4 Otelixizumab 106
6.4.5 Alogliptin 106
6.4.6 Oral-Lyn 107
6.4.7 Dapagliflozin 108
6.4.8 Canagliflozin 109
6.4.9 MB07803 110
7 Diabetes Therapeutics Market to 2017 - Competitive Landscape 111
7.1 Diabetes Market Overview 111
7.1.1 Human Insulin Products and Oral Antidiabetic Drugs like Actos Group (Actos and Actoplus Met) and Lantus Have Led Market Growth 111
7.2 Market Share Analysis - Diabetes 112
7.2.1 Market Share Analysis by Company - 2010 112
7.2.2 Market Share Analysis by Company - 2017 113
7.3 Market Share Analysis by Class for the Anti-Diabetic Drugs 114
7.3.1 Market Share Analysis by Drug Class - 2010 114
7.3.2 Market Share Analysis by Drug Class - 2017 115
7.4 Competitive Profiling 116
7.4.1 Novo Nordisk 116
7.4.2 Sanofi 121
7.4.3 Takeda 126
7.4.4 Eli Lilly 129
7.4.5 GlaxoSmithKline (GSK) 135
7.4.6 Merck & Co Inc 139
7.4.7 Amylin Pharmaceuticals 142
8 Diabetes Therapeutics Market to 2017 - M&A Landscape 146
8.1 Overview 146
8.2 Mergers and Acquisitions (M&A) 148
8.2.1 Strategic Consolidation 148
8.2.2 M&A Deals by Value 149
8.2.3 Major Mergers and Acquisitions 150
8.2.4 M&A Deals by Geography 151
8.2.5 M&A Deals by Indication 152
8.3 Licensing Agreements 153
8.3.1 Licensing by Geography 153
8.3.2 Major Licensing Agreements 154
8.3.3 Licensing Agreements by Indication 156
8.3.4 Licensing Agreements by Value 157
8.4 Co-Development 158
8.4.1 Co-Development by Geography 158
8.4.2 Major Co-Development Deals 159
8.4.3 Co-Development by Indication 161
8.4.4 Co-Development by Value 162
9 Diabetes Therapeutics Market to 2017 - Appendix 163
9.1 Market Definitions 163
9.2 Abbreviations 163
9.3 Research Methodology 163
9.3.1 Coverage 164
9.3.2 Secondary Research 164
9.3.3 Primary Research 165
9.3.4 Forecasts 165
9.3.5 Expert Panel Validation 167
9.4 Contact Us 168
9.5 Disclaimer 168
9.6 Sources 168
1.1 List of Tables
Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2003-2010 16
Table 2: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16
Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2010 18
Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 18
Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2003-2010 19
Table 6: Diabetes Therapeutics Market, The US, Revenue ($bn), 2003-2010 29
Table 7: Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 29
Table 8: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2010 30
Table 9: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 30
Table 10: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2003-2010 31
Table 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017 32
Table 12: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue, $bn, 2003-2010 38
Table 13: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2010-2017 38
Table 14: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2010 39
Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 39
Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2003-2010 40
Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2017 41
Table 18: Diabetes Therapeutics Market, Japan, Revenues ($bn), 2003-2010 46
Table 19: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 46
Table 20: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2010 47
Table 21: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 47
Table 22: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2003-2010 48
Table 23: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017 48
Table 24: Diabetes Therapeutics Market, Type 1 Diabetes Market, Types of Insulin Regimen 54
Table 25: Type 1 Diabetes Market, Global, Revenues ($bn), 2003-2010 57
Table 26: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017 57
Table 27: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010 58
Table 28: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017 59
Table 29: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010 61
Table 30: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017 61
Table 31: Type 2 Diabetes Market, Global, Revenues ($bn), 2003-2010 71
Table 32: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017 71
Table 33: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010 72
Table 34: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017 72
Table 35: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010 74
Table 36: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017 74
Table 37: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011 82
Table 38: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Pre-Clinical, 2011 83
Table 39: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011 84
Table 40: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011 85
Table 41: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011 88
Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011 88
Table 43: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011 90
Table 44: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, IND Filed, 2011 91
Table 45: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011 91
Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011 94
Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011 98
Table 48: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011 99
Table 49: Diabetes Therapeutics Market, Factors Determining Preference of Drug Delivery in Diabetes 101
Table 50: Diabetes Therapeutics Market, Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable 102
Table 51: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2011 120
Table 52: Diabetes Therapeutics Market, Sanofi, Pipeline Products, 2011 125
Table 53: Diabetes Therapeutics Market, Takeda, Pipeline Products, 2011 128
Table 54: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2011 134
Table 55: Diabetes Therapeutics Market, GSK, Pipeline Products, 2011 138
Table 56: Diabetes Therapeutics Market, Merck, Pipeline Products, 2011 141
Table 57: Diabetes Therapeutics Market, Amylin, Pipeline Products (%), 2010 144
Table 58: Diabetes Therapeutics Market, Global, Strategic Consolidation, 2004-2011 148
Table 59: Diabetes Therapeutics Market, Global, Number of M&A Deals by Value, 2004-2011 149
Table 60: Diabetes Therapeutics Market, Global, Mergers and Acquisitions, 2010-2011 150
Table 61: Diabetes Therapeutics Market, Global, Number of M&A Deals by Geography, 2004-2011 151
Table 62: Diabetes Therapeutics Market, Global, Number of M&A Deals by Indication, 2004-2011 152
Table 63: Diabetes Therapeutics Market, Global, Number of Licensing Agreements by Geography, 2004-2011 153
Table 64: Diabetes Therapeutics Market, Global, Licensing Agreements, 2010-2011 154
Table 65: Diabetes Therapeutics Market to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011 156
Table 66: Diabetes Therapeutics Market to 2017, Number of Licensing Agreements by Value, Global, 2004-2011 157
Table 67: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Geography, 2004-2011 158
Table 68: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals, 2010-2011 159
Table 69: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication, 2004-2011 161
Table 70: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Value, 2004-2011 162
1.2 List of Figures
Figure 1: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2017 15
Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2017 17
Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns, 2003-2017 19
Figure 4: Diabetes Therapeutics Market, Global, Prevalence Population, 2003-2017 21
Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population, 2003-2017 22
Figure 6: Diabetes Therapeutics Market, Global, Diagnosed Population, 2003-2017 23
Figure 7: Diabetes Therapeutics Market, Global, Prescription Population, 2003-2017 24
Figure 8: Diabetes Therapeutics Market, Global, Drivers and Restraints 25
Figure 9: Diabetes Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2010 27
Figure 10: Diabetes Therapeutics Market, The US, Revenue Forecasts, ($bn), 2003-2017 28
Figure 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2017 30
Figure 12: Diabetes Therapeutics Market, The US, Treatment Usage Patterns, 2003-2017 31
Figure 13: Diabetes Therapeutics Market, The US, Prevalence Population, 2003-2017 33
Figure 14: Diabetes Therapeutics Market, The US, Treatment Seeking Population, 2003-2017 34
Figure 15: Diabetes Therapeutics Market, The US, Diagnosed Population, 2003-2017 35
Figure 16: Diabetes Therapeutics Market, The US, Prescription Population, 2003-2017 36
Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2003-2017 37
Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2017 39
Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2003-2017 40
Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Prevalence Population, 2003-2017 42
Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population, 2003-2017 43
Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosed Population, 2003-2017 44
Figure 23: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population, 2003-2017 45
Figure 24: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2003-2017 46
Figure 25: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2017 47
Figure 26: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2003-2017 48
Figure 27: Diabetes Therapeutics Market, Japan, Prevalence Population, 2003-2017 49
Figure 28: Diabetes Therapeutics Market, Japan, Treatment Seeking Population, 2003-2017 50
Figure 29: Diabetes Therapeutics Market, Japan, Diagnosed Population, 2003-2017 51
Figure 30: Diabetes Therapeutics Market, Japan, Prescription Population, 2003-2017 52
Figure 31: Type 1 Diabetes Market, Global, Unmet Needs 55
Figure 32: Type 1 Diabetes Market, Global, Branded vs. Generic Market Share (%), 2010 56
Figure 33: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017 57
Figure 34: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017 58
Figure 35: Type 1 Diabetes Market, Global, Treatment Flow Algorithm 60
Figure 36: Type 1 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017 61
Figure 37: Type 1 Diabetes Market, Global, Prevalence Population, 2003-2017 62
Figure 38: Type 1 Diabetes Market, Global, Treatment Seeking Population, 2003-2017 63
Figure 39: Type 1 Diabetes Market, Global, Diagnosed Population, 2003-2017 64
Figure 40: Type 1 Diabetes Market, Global, Prescription Population, 2003-2017 65
Figure 41: Type 1 Diabetes Market, Global, Diabetes Market Drivers and Restraints 67
Figure 42: Type 2 Diabetes Market, Global, Unmet Needs 69
Figure 43: Type 2 Diabetes Market, Global, Branded vs Generic Market Share, 2010 70
Figure 44: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017 71
Figure 45: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017 72
Figure 46: Type 2 Diabetes Market, Global, Treatment Flow Algorithm 73
Figure 47: Type 2 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017 74
Figure 48: Type 2 Diabetes Market, Global, Prevalence Population, 2003-2017 75
Figure 49: Type 2 Diabetes Market, Global, Treatment Seeking Population, 2003-2017 76
Figure 50: Type 2 Diabetes Market, Global, Diagnosed Population, 2003-2017 77
Figure 51: Type 2 Diabetes Market, Global, Prescription Population, 2003-2017 78
Figure 52: Type 2 Diabetes Market, Global, Market Drivers and Restraints, 2010-2017 79
Figure 53: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 81
Figure 54: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 82
Figure 55: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011, 89
Figure 56: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2010 112
Figure 57: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2017 113
Figure 58: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2010 114
Figure 59: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2017 115
Figure 60: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Segment (%), 2010 116
Figure 61: Diabetes Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product (%), 2010 117
Figure 62: Diabetes Therapeutics Market, SWOT Analysis, Novo Nordisk 120
Figure 63: Diabetes Therapeutics Market, Sanofi, Revenue by Segment (%), 2010 121
Figure 64: Diabetes Therapeutics Market, Sanofi, Diabetes Revenue by Product (%), 2010 122
Figure 65: Diabetes Therapeutics Market, SWOT Analysis, Sanofi 125
Figure 66: Diabetes Therapeutics Market, Takeda, Revenue by Segment (%), 2010 126
Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Takeda 128
Figure 68: Diabetes Therapeutics Market, Eli Lilly, Revenue by Segment (%), 2010 129
Figure 69: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2010 130
Figure 70: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly 134
Figure 71: Diabetes Therapeutics Market, GSK, Revenue by Segment (%), 2010 135
Figure 72: Diabetes Therapeutics Market, SWOT Analysis, GSK 138
Figure 73: Diabetes Therapeutics Market, Merck, Revenue by Segment, 2010 139
Figure 74: Diabetes Therapeutics Market, SWOT Analysis, Merck 141
Figure 75: Diabetes Therapeutics Market, Amylin, Revenue by Segment (%), 2010 142
Figure 76: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2010 143
Figure 77: Diabetes Therapeutics Market, SWOT Analysis, Amylin 145
Figure 78: Diabetes Therapeutics Market, Global, Strategic Consolidation (%), 2004-2011 148
Figure 79: Diabetes Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011 149
Figure 80: Diabetes Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011 151
Figure 81: Diabetes Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2011 152
Figure 82: Diabetes Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011 153
Figure 83: Diabetes Therapeutics Market, Global, Licensing Agreements by Indication (%), 2004-2011 156
Figure 84: Diabetes Therapeutics Market to 2017, Global, Licensing Agreements by Value (%), 2004-2011 157
Figure 85: Diabetes Therapeutics Market to 2017, Global, Co-Development by Geography (%), 2004-2011 158
Figure 86: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication (%), 2004-2011 161
Figure 87: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals by Value (%), 2004-2011 162
Figure 88: Diabetes Therapeutics Market, GBI Research Market Forecasting Model 167
Companies mentioned
Novo Nordisk
Sanofi
Takeda
Eli Lilly
GlaxoSmithKline (GSK)
Merck & Co Inc
Amylin Pharmaceuticals
To order this report:
Therapy Industry: Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker